Clinical Trials Logo

Latent Tuberculosis Infection clinical trials

View clinical trials related to Latent Tuberculosis Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06033807 Recruiting - Tuberculosis Clinical Trials

Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to investigate the proportion of Mycobacterium tuberculosis (MTB) infection in school contacts of active tuberculosis (ATB) patients. The main questions it aims to answer are: - the proportion of MTB infection among school contacts of ATB patients - risk factors related to tuberculosis (TB) infection - health economic evaluation of screening strategy

NCT ID: NCT05899179 Recruiting - Clinical trials for Latent Tuberculosis Infection

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Start date: August 3, 2023
Phase: Phase 3
Study type: Interventional

A multicenter, randomized, blind, controlled trial design was used to select 240 tuberculosis (TB) patients, 120 non-tuberculous community population with other lung diseases, and 420 healthy community population without other lung diseases who met the inclusion criteria of this study. Blood supply specific gamma-interferon (T-SPOT) detection was performed first. Then, EC and Purified Protein derivation of tuberculin (TB-PPD) skin tests were performed on both arms, and the recorded results were observed. The first 24 cases of TB patients, the first 12 cases of non-tuberculous community population with other lung diseases, and the first 42 cases of healthy community population without other lung diseases were included in the trial subgroup. Physical examination, blood routine, urine routine, liver and kidney function, and electrocardiogram tests were required before and 7 days after skin test after study number assignment.

NCT ID: NCT05746611 Recruiting - Clinical trials for Latent Tuberculosis Infection

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Start date: April 17, 2023
Phase: Phase 4
Study type: Interventional

Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only

NCT ID: NCT05680415 Recruiting - Clinical trials for Latent Tuberculosis Infection

Clinical Trial of Mica

Start date: April 19, 2023
Phase: Phase 4
Study type: Interventional

This study used a randomized, open, blank control design. A total of 6800 patients over 15 years old with latent mycobacterium tuberculosis infection who met the inclusion criteria but did not meet the exclusion criteria were randomly assigned to the experimental group and the blank control group in a 1:1 ratio, with 3400 patients in each group. The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, with a total of 6 doses. The blank control group was not injected with drugs.

NCT ID: NCT03312647 Recruiting - Clinical trials for Latent Tuberculosis Infection

Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection

Start date: June 19, 2017
Phase: N/A
Study type: Observational

The investigators aim to study the prevalence of adverse reactions of anti-tuberculosis (TB) drugs in latent tuberculosis infection (LTBI), and determine the risk factors of anti-TB drug-related toxicity in LTBI in Korean health care workers(HCWs).

NCT ID: NCT00905970 Recruiting - Clinical trials for Latent Tuberculosis Infection

Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection

HYPDYN
Start date: May 2009
Phase: N/A
Study type: Observational

It is traditionally considered that the development of Latent Tuberculosis Infection (LTBI) is due to the M. tuberculosis ability to develop a dormancy state within well-structured lesions (granulomas), which can remain in the lung of the host even for life. A new original hypothesis has been developed in the Experimental Tuberculosis Unit based on scientific evidence that take into account the idea that a lesion cannot be held forever, because the host tends to remove any lesion in order to rebuild the original parenchyma, in a healing process. Even if M. tuberculosis can remain in a dormant/non-replicating state for a long period, this is an important but not sufficient factor to explain the LTBI. The Dynamic Hypothesis tries to explain the existence of LTBI in spite of the healing process that could remove it by a constant reinfection of the host's tissue. While the "Static" view defends the induction of active TB after the reactivation of the bacilli from and old lesion; while the "Dynamic" view wants to demonstrate that there is a constant induction of new granulomas. In case one of these new lesions takes place in the upper lobe privileged zone, the possibility to induce a cavity would appear, developing an active Tuberculosis (TB).

NCT ID: NCT00692809 Recruiting - HIV Infections Clinical Trials

Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection

HIV-TB
Start date: July 2008
Phase: N/A
Study type: Observational

HIV induced altered representation and function of regulatory T cell subsets (NKT and Treg cells) impair the protective T cell response against M.tuberculosis and disrupts LTBI, thus facilitates faster progression and development of severe forms of clinical TB in HIV-TB co-infection.

NCT ID: NCT00449345 Recruiting - Clinical trials for Latent Tuberculosis Infection

Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis

Start date: May 2007
Phase: N/A
Study type: Observational

The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable. In recent years, more specific and sensitive tests based on interferon-gamma secretion to TB antigens have come to market, and most current evidence shows that many mantoux positive persons do not have LTBI. Quantiferon-GOLD is one of these assays. In this prospective study, we will draw blood for the Quantiferon-GOLD assay in parallel to conventional testing, and perform a cost-effectiveness analysis of the cost of the investigation and treatment of LTBI in health-care workers. We hypothesize that in spite of the cost of screening healthcare workers with Quantiferon-GOLD tests, the reduction in need for LTBI treatment and associated costs will render the test cost-effective.